Mirum Pharmaceuticals Current Deferred Revenue Over Time
| MIRM Stock | USD 46.65 1.50 3.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mirum Pharmaceuticals Performance and Mirum Pharmaceuticals Correlation. Mirum |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 6.513 | Quarterly Revenue Growth 0.894 | Return On Assets (0.09) | Return On Equity (0.40) |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Mirum Pharmaceuticals and related stocks such as Immunocore Holdings, Larimar Therapeutics, and Kalvista Pharmaceuticals Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMCR | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 27.1 M | 24.4 M | 6.4 M | 5.5 M | 5.2 M |
| LRMR | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.6 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| KALV | 23 K | 23 K | 23 K | 29 K | 29 K | 29 K | 18.5 M | 18.5 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 11 M | 11.5 M |
| LYRA | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 2.8 M | 9.8 M | 1.3 M | 1.7 M | 3 M |
| TERN | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 1.2 M | 1.2 M | 1.4 M | 1.1 M |
| INZY | 279 K | 279 K | 279 K | 279 K | 279 K | 279 K | 279 K | 279 K | 279 K | 279 K | 279 K | 3.8 M | 3.8 M | 4.4 M | 2.2 M |
| XFOR | 430 K | 430 K | 430 K | 430 K | 430 K | 430 K | 504 K | 2.6 M | 737 K | 737 K | 737 K | 737 K | 737 K | 847.5 K | 1.2 M |
| DAWN | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 6.6 M | 25.5 M | 29.3 M | 30.8 M |
| MLTX | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (185.5 K) | (166.9 K) | (175.3 K) |
| APLS | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 103.2 M | 103.2 M | 92.9 M | 86.1 M |
| BPMC | 1 M | 1 M | 1 M | 1 M | 3.9 M | 5.9 M | 11.4 M | 5.4 M | 3.6 M | 6.2 M | 12.6 M | 36.6 M | 448.6 M | 812 K | 771.4 K |
Mirum Pharmaceuticals and related stocks such as Immunocore Holdings, Larimar Therapeutics, and Kalvista Pharmaceuticals Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Mirum Pharmaceuticals | MIRM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 46.65
Check out Mirum Pharmaceuticals Performance and Mirum Pharmaceuticals Correlation. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Mirum Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.